Clinical trial
Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of…
NCT00358098 · AHS Cancer Control Alberta, Other · Terminated
Key facts
| NCT number | NCT00358098 |
|---|---|
| Title | Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer |
| Official title | For Women With Estrogen Positive Metastatic Breast Cancer Discordance of Pre-treatment FDG-PET and FES-PET in Addition to Presence of Ki-67 and Human Epidermal Growth Factor 2 (HER-2) Overexpression Will Predict for Hormone Refractory Disease When Compared to Standard Response Criteria |
| Lead sponsor | AHS Cancer Control Alberta, Other |
| Status | Terminated |
| Study type | Observational |
| Conditions | Metastatic Breast Cancer |
| Enrollment | 51 |
| Start date | Aug 1, 2006 |
| Primary completion | Jun 1, 2013 |
| Completion | Jun 1, 2013 |
| First posted | Jul 28, 2006 |
| Last update posted | Jun 21, 2024 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: